Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database
- 16 April 2025
- journal article
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 96, 12-14
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
- Agence Nationale de la Recherche (ANR-23-CE36\u20130006)
- National Institute for Health and Care Research
- European Commission
This publication has 5 references indexed in Scilit:
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-AnalysisAmerican Journal of Psychiatry, 2025
- Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depressionEuropean Neuropsychopharmacology, 2024
- Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 studyNeuropsychopharmacology, 2023
- Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting SystemPsychotherapy and Psychosomatics, 2020
- Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant DepressionJAMA Psychiatry, 2019